

 Early Warning System

EIB-20240179

IO BIOTECH (IEU LS)



Quick Facts

Countries	Denmark
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2024-12-19
Borrower	IO BIOTECH APS
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 39.39 million
Project Cost (USD)	\$ 103.65 million



Project Description

According to the Bank's website, IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccine therapies based on an innovative proprietary technology platform. The project involves the development of an innovative immunotherapeutic cancer vaccine to treat melanoma. With its broad applicability, this vaccine has the potential to become the new standard of care in cancer treatment.

The project's objectives are:

- (i) finalising the development of the company's lead product candidate
- (ii) expanding the company's pipeline of product under development
- iii) strengthening the company's technology platform.



Early Warning System Project Analysis

According to the Environmental and Social Data Sheet, the Promoter has effective environmental and social policies and operating procedures in place, which are in line with current industry standards. Additionally, this project schedules investments in research and development for which no likely significant impact on the environment is expected.



Investment Description

- European Investment Bank (EIB)



Private Actors Description

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	IO Biotech APS	Client	-



Contact Information

Contact: Tim Smit

Email: t.smit@eib.org

Phone: + 352 4379 – 89076

ACCESS TO INFORMATION

You can submit an information request for project information at: <https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm>

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: <http://www.eib.org/complaints/form> via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: <http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces>



Bank Documents

- [Environmental and Social Data Sheet \(ESDS\) - IO BIOTECH \(IEU LS\)](#)

Media

- [Denmark: IO Biotech secures up to €57.5 million EIB venture debt to advance cancer vaccine research](#)



Other Related Projects

- EIB-20220302 LIFE SCIENCES (INVESTEU VD) PL